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Abstract
Background
Comparison of changes in body composition, adipokines and inflammatory markers after ini-
tial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or contain-
ing regimen are scarce.
Design
Randomised Clinical Trial.
Methods
This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial compar-
ing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/
emtricitabine (TDF/FTC) in 805 ART naïve HIV-infected adults. The primary endpoint was
percentage change in limb fat at week 96. Secondary endpoints were associations among
these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23).
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Results
126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change
in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period
(p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean
mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9%
(p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were corre-
lated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for
limb fat, and r = 0.63 (p<0.0001)/r = 0.50(p<0.0001) for trunk fat]. After adjustment, a 10%
faster increase in leptin between baseline and week 48 was associated with a more rapid
increase in limb fat at week 48 (0.5% per 48 weeks, p<0.001), total body fat mass (0.6% per
48 weeks, p<0.001), and trunk fat mass (0.3% per 48 weeks, p = 0.0026).
Conclusions
After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater
percentage increase in body composition variables with only change in trunk fat mass and
BMI being significant.
Introduction
HIV-infected patients receiving currently guideline-recommended 1st line antiretroviral ther-
apy (ART) rarely develop visible alterations in fat distribution[1]. Lipoatrophy has been linked
to the use of thymidine nucleoside reverse transcriptase inhibitors as a consequence of mito-
chondrial toxicity[2,3]. The nucleos(t)ide reverse transcriptase inhibitors (N(t)RTI) combina-
tions currently in use (abacavir/lamivudine and tenofovir disoproxil fumarate/emtricitabine)
are not considered to be related with clinical lipoatrophy although in the A5224 substudy both
N(t)RTIs similarly decreased mitochondrial DNA in fat biopsies[4]. Although lipohypertrophy
was initially thought to be the hallmark of exposure to protease inhibitors[5], recent trials have
reported increases in visceral fat with most ART drugs including non-nucleosides reverse tran-
scriptase inhibitors and integrase inhibitors [6,7].
Obesity and visceral adiposity are increasing concerns in people living with HIV especially
in the era of modern antiretroviral therapy. In addition to traditional risk factors, HIV- and
ART-related factors may also play a role.
Recent data from the ACTG 5202 and two different HIV-uninfected cohorts have shown
that HIV-infected patients gained fat and lean mass in the first two years after initiating antire-
troviral treatment but in the long term they lost lean body mass and gained trunk fat[8]. These
body composition changes are relevant because they are associated with an increased risk of
diabetes, liver disease, atherosclerosis and cardiovascular disease. Therefore it is important to
investigate the contribution of different ART drugs to visceral adiposity.
Data regarding body composition changes with N(t)RTI sparing regimens in ART-naïve
patients are limited. In the PROGRESS study a combination of lopinavir/ritonavir plus ralte-
gravir (RAL) led to greater increases in peripheral fat over 96 weeks compared with lopinavir/
ritonavir plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)[9]. The RADAR study
comparing a combination of darunavir/ritonavir (DRV/r) plus RAL with DRV/r plus TDF/
FTC found no evidence of significant differences in total body fat or lean fat mass over 48
weeks[10].
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Chronic inflammation and immune activation associated with HIV infection could modu-
late visceral adiposity changes seen in HIV-infected individuals under long-term antiretroviral
therapy[11,12]. There is some evidence of an association between chronic inflammation and
increases in visceral adipose tissue in patients with lipodystrophy[13]. Few studies have looked
into the associations between antiretroviral drugs, body composition changes and adipokines
and some have raised the hypothesis that increases in visceral adipose tissue could be associ-
ated with higher leptin and lower adiponectin levels[7,14].
NEAT 001/ANRS 143 evaluated the virologic efficacy and tolerability of ritonavir-boosted
darunavir in combination with tenofovir disoproxil fumarate (TDF)-emtricitabine or raltegra-
vir in treatment naïve HIV-infected adults in Europe[15]. In the current report, we examined
the body composition effect, as well as adipokines and metabolic biomarkers changes over 96
weeks after starting ART.
Patients and methods
NEAT 001/ANRS 143 was a randomised, open-label, 96 weeks, non-inferiority trial of ART-
naïve conducted in 78 clinical sites in 15 European countries between August 2010 and Octo-
ber 2013. The present substudy was conducted over 19 clinical sites. Inclusion criteria were:
HIV RNA greater than 1000 copies per mL and CD4 cell count under 500 cells per μL in ART-
naïve participants and no evidence of major International Antiviral Society-USA resistance
mutations. Exclusion criteria were: receiving treatment for mycobacteriosis or malignant dis-
ease, tested positive for HBsAg, pregnancy, relevant laboratory abnormalities and an estimated
creatinine clearance less than 60 mL/min. Additional exclusion criteria for the bone mineral
density and body composition sub-studies were: treatment for osteoporosis and concomitant
use of steroids or oestrogen replacement therapy at screening [15,16].
Any patient enrolling NEAT001/ANRS143 study in a site participating in the bone mineral
density substudy and fulfilling the inclusion criteria was suitable for this pre-planned analysis.
Randomisation was performed at the same time for the parent study and after having con-
sented for the bone mineral density substudy. Briefly, patients were enrolled into the substudy
before being randomised in the core trial to receive 800 mg darunavir and 100 mg ritonavir
once daily plus 400 mg raltegravir twice daily [N(t)RTI-sparing regimen] or 800 mg darunavir
and 100 mg ritonavir plus tenofovir disoproxil fumarate/emtricitabine in a 300 mg and 200
mg fixed-dose combination. The primary endpoint of this body composition analysis was the
mean percentage change of limb fat mass between baseline (randomisation) and week 96. The
secondary endpoints included: mean percentage change of trunk fat mass, total body fat and
total body lean mass and body mass index (BMI) at 96 weeks, predictors of body composition
changes and associations between adipokines and inflammatory markers with body composi-
tion changes. The study protocol was approved by the Ethics Committee Regional de Madrid
in accordance with the principles of the Declaration of Helsinki. The study was also approved
by individual ethics committees in the following centres: Ethikkomission der Stadt Wien, Uni-
versitair Ziekenhuis Antwerpen, Region Hovedstaden De Videnskabseliske Komiteer, CPP Ile
de France VI Groupe Hospitalier Pitie´ Salpatreire, Hanover School of Medicine, Hellenic
Republic Minister of Health and Welfare National ethic committee, Medical research council
Ethics committee in Hungary, Mater Private Hospital Research Ethics Committee, Centrum
Medyczne Ksztakcenia podyplomowego Komisja Biothyczna, Comissao de Etica para a Inves-
tigacao Clinica, Karolinska university hospital regional etikprovningsnamnden i Stockholm,
NHS leeds East Research Ethics Committee and Medisch Ethische Toetsingscommissie Acade-
misch Medisch Centrum. All trial participants gave specific written informed consent for the
bone mineral density substudy and the parent study at the same time and therefore were
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included in this body composition substudy prior to randomised treatment allocation. (Clini-
calTrials.gov registration number NCT01066962).
Study procedures
Whole body dual energy X-ray absorptiometry (DXA) scans using either Hologic (Hologic
Inc., Bedford, Massachusetts, USA) or GE Lunar (GE Healthcare Lunar, Madison, Wisconsin,
USA) devices were performed at baseline, weeks 48 and 96. Total limb fat (upper plus lower
extremities fat), trunk fat, total body lean mass and total body fat mass were quantified using
standardized scanning protocols and locally calibrated based on each manufacturer’s specifica-
tions. Technicians -blinded to study clinical information- were instructed to use the same
device on the same patient during the trial without central reading.
Adipokines and markers of inflammation were performed in the department of Laboratory
Medicine at Hospital Universitario La Paz, Madrid on batched serum samples stored at -80˚C
from weeks 0 and 48. The following markers were analysed: IL-6; IL-1β; TNF-α, Insulin, Lep-
tin, Adiponectin and Fibroblast Growth Factor-23 (FGF-23) with a multiplex magnetic bead
panel assay (HBNMAG-51 Merck Millipore) using a Luminex 200 analyzer.
Statistical analysis
Sample size was calculated for bone mineral density changes. We calculated that 64 patients
per arm would provide 80% power to detect a treatment difference of 2.5% in BMD in lumbar
spine assuming a standard deviation of 5 and a 2-sided t-test with alpha of 0.05. Assuming a
10% drop out rate a total of 142 patients would be needed. All analysis were performed in an
intent to treat approach (participants who changed treatment during the study were analysed
in the same groups as at randomisation).
Descriptive statistics were used to summarise patient characteristics in each treatment arm
and were compared using chi-squared tests, unpaired t-tests or non-parametric Wilcoxon
tests. Percentage changes in body composition variables from baseline to week 48 and baseline
to week 96 were assessed and compared between treatment arms using mixed models with a
random intercept and allowing for repeated observations per patient. This method estimates
the difference in the rate of change between treatment arms and the difference was standard-
ised per 48-week period. Multivariable models were adjusted for factors that were associated
with changes in univariable analyses with p<0.1. Mixed models were also used to assess
whether the percentage change in biomarkers were associated with changes in body composi-
tion from baseline to week 48. Any adipokines or inflammatory markers that were significant
in univariable analyses (p<0.1) were included in the multivariable analysis. Sensitivity analysis
was planned using medians and non-parametric tests, and also including laboratory variables
as binary (>5% change).
Statistical analyses were performed using SAS (Statistical Analysis Software; Cary, NC,
USA) Version 9.3. All tests of significance were 2-sided.
Results
A total of 146 subjects were included and randomized. The intention-to-treat-exposed popula-
tion comprised 126 subjects with at least one DXA performed, 61 subjects in the DRV/r
+ RAL group and 65 subjects in the DRV/r + TDF/FTC, of whom 48 and 56, respectively, com-
pleted week 96 (Fig 1). Baseline characteristics were well balanced between groups (Table 1)
and did not differ from those of the core trial (data not shown). Participants were 90.5% male
and 82% Caucasian. The median age was 40 years (IQR 31–46); median CD4 count was 338
cells/mm3 (IQR 279–407); median viral load was 4.7 log10 copies/mL (IQR 4.3–5.1); median
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body mass index (BMI) was 23.2 Kg/m2 (IQR 21.4–26.2); and median waist to hip ratio was
0.91 (IQR 0.86–0.98).
There were no statistical differences between groups in body composition at randomization
except for a median higher total body fat mass in the DRV/r + TDF/FTC group [17.1 kg (IQR
11–19.8) vs. 14.3 kg (IQR 9.8–22.9); p = 0.014] (Table 1).
Changes in body composition
There was a small but significant increase in BMI in both arms from baseline to week 48 and
baseline to week 96. The rate of change in the DRV/r + TDF/FTC group was 2.2% per 48 week
period (95% CI 0.6–3.7, p = 0.0074) at week 48 and 1.0% per 48 week period (95% CI 0.2–0.8,
p = 0.023). The rate of change was higher in the DRV/r + RAL group at both 48 weeks (differ-
ence 2.1% per 48 week period; 95% CI -0.2–4.2;p = 0.078) and 96 weeks (difference 1.5% per
48 week period; 95% CI 0.3–2.6;p = 0.015).
Of the 126 patients included in the current analysis, 115 (53 in the DRV/r + RAL arm and
62 in the DRV/R + TDF/FTC arm) had a DXA performed at 48 week and 114 (48 in the
Fig 1. Flow chart of NEAT001/ANRS143 body composition substudy.
https://doi.org/10.1371/journal.pone.0209911.g001
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DRV/r + RAL arm and 56 in the DRV/R + TDF/FTC arm) at 96 week. Body composition vari-
ables increased from baseline to week 48 and baseline to week 96 in the combined study popu-
lation and in both treatment groups, with higher increases in the DRV/r +RAL groups (Fig 2),
particularly for limb fat mass, trunk mass, total body lean mass and total body fat. For example,
the rate of change in limb fat mass was higher at 48 weeks for DRV/r + RAL versus DRV/r
+ TDF/FTC (8.9% per 48 week period; 95% CI -4.5–22.2, p = 0.20) and at 96 weeks (2.5% per
48 week period; 95% CI -3.0–7.8, p = 0.38), although not statistically significant. The largest
differences in the rate of change comparing DRV/r + RAL versus DRV/r + TDF/FTC were
seen for trunk fat at week 96 (7.3% per 48 week period, 95% CI 1.2–13.3, p = 0.021), total body
lean mass at 48 weeks (11.0% per 48 week period; 95% CI 0.3–21.8%, p = 0.046) and in total
body mass at 48 weeks (9.1% per 48 week period, 95% CI -0.8–18.9%, p = 0.072) and 96 weeks
(4.9% per 48 week period; 95% CI -0.2–10.0, p = 0.061).
Although globally there was a trend for increases in fat, there were some participants with
fat loss. Indeed, 33 participants (26%) had a limb fat loss� 10% and 18 participants (14.4%)
Table 1. Baseline characteristics.
DRV/r + RAL
(N = 61)
DRV/r + TDF/FTC
(N = 65)
Total
(N = 126)
Gender (Male): n (%) 53 (86.9) 61 (93.9) 114 (90.5)
Age, years: Median (IQR) 39 (31–45) 40 (32–46) 40 (31–46)
Ethnicity: n (%)
Caucasian 50 (82) 53 (81.5) 103 (81.7)
Other 11 (18) 12 (18.5) 23 (18.3)
Current Smoking: n (%) 25 (41%) 31 (47.7%) 56 (44.4%)
Current Alcohol use: n (%) 3 (4.9) 2 (3.1) 5 (4%)
Baseline HIV-1 RNA, log 10 copies/ml: Median (IQR) 4.8 (4.3–5.2) 4.7 (4.4–5.0) 4.7 (4.3–5.1)
Baseline CD4+, cells/mm3: Median (IQR) 347 (280–393) 331 (278–414) 338 (279–407)
CD4 + nadir, cells/mm3: Median (IQR) 327 (236–370) 327 (268–374) 327 (260–374)
Weight, Kg: Median (IQR) 72 (64–80) 72 (67–81) 72 (65–80)
BMI, Kg/ m2: Median (IQR) 22.4 (20.9–26.1) 23.4 (21.7–26.3) 23.2 (21.4–26.2)
Waist, cm: Median (IQR) 82 (77–89) 84 (79–93) 84 (78–91)
Hip, cm: Median (IQR) 92 (86–99) 94 (87–99) 93 (86–99)
Waist: hip ratio: Median (IQR) 0.92 (0.85–0.97) 0.91 (0.87–0.98) 0.91 (0.86–0.98)
Total body fat mass, Kg: Median (IQR) 14.3 (9.8–22.9) 17.1 (11–19.8) 15.4 (10.7–21.9)
Limb fat, Kg: Median (IQR) 6.7 (4.7–10.3) 6.4 (5.2–9.1) 6.7 (4.7–9.7)
Trunk fat, Kg: Median (IQR) 7.8 (4.6–11.9) 8.8 (5.4–11.6) 8.5 (4.5–11.7)
Lean body mass, Kg: Median (IQR) 49.2 (45.1–52.5) 50.5 (46.8–54.4) 50.1 (46.1–54.2)
Walking hours/week: Median (IQR) 4 (2–6) 4 (2–7) 4 (2–7)
IL-6, pg/mL: Mean (95%CI) 1.2 (0.0–2.4) 1.4 (0.6–2.2) 1.3 (0.5–2.1)
IL-1β, pg/dL: Mean (95%CI) 0.4 (0.3–0.5) 0.4 (0.3–0.5) 0.4 (0.3–0.5)
TNF-α, pg/dL: Mean (95%CI) 4.1 (2.7–5.5) 4.0 (3.6–4.4) 4.0 (3.4–4.6)
Insulin, μU/ml: Mean (95%CI) 6.3 (2.6–10) 5.1 (3.9–6.3) 5.6 (3.8–7.4)
Leptin, ng/mL: Mean (95%CI) 5.58 (3.01–8.15) 4.45 (2.67–6.21) 4.96 (3.45–6.48)
Adiponectin, mcg/mL: Mean (95%CI) 23.9 (19–28.8) 15.8 (13.3–18.3) 19.5 (16.8–22.2)
FGF-23, pg/mL: Mean (95%CI) 36.5 (32–41) 38.8 (35.1–42.5) 37.7 (34.8–40.6)
HOMA-IR: Mean (95% CI) 1.6 (0.97–2.23) 1.97 (0.6–3.34) 1.30 (0.99–1.61)
DRV/r, darunavir/ritonavir; RAL, raltegravir; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine, BMI: body mass index; IL, interleukin; TNF, tumour necrosis
factor; FGF, fibroblast growing factor; HOMA-IR, homeostatic model assessment-insulin resistance
https://doi.org/10.1371/journal.pone.0209911.t001
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lost� 20% of limb fat, but differences in proportions with limb fat loss� 10% or� 20% were
not statistically significant between treatment arms (p = 0.12 and p = 0.28 respectively).
Associations between adipokines/inflammatory markers and body
composition
We measured at least one of the inflammatory markers in 87 patients. Absolute baseline values
for adipokines and inflammatory biomarkers were similar between treatment groups except
for adiponectin [15.8 mcg/mL in DRV/r + TDF/FTC vs. 23.9 mcg/mL in DRV/r + RAL; mean
difference -8.1 (95% CI -13.5, -2.7); p = 0.004]. Correlations between baseline adipokines,
inflammatory markers and body composition variables (limb, trunk and total body fat) were
weak except for leptin r = 0.63 (p<0.0001), r = 0.50 (p<0.0001) and r = 0.63 (p<0.0001)
respectively. Other significant correlations were between baseline insulin and baseline limb
Fig 2. Changes in body composition variables over 96 weeks. (A) Mean (95% CI) percentage rate of change in limb fat. (B) Mean (95% CI) percentage rate of change in
trunk fat. (C) Mean (95%CI) percentage rate of change in total body lean mass. (D) Mean (95%CI) percentage rate of change in total body fat mass. Abbreviations: DRV/r,
Darunavir/ritonavir; RAL, Raltegravir; TDF/FTC, Tenofovir disoproxil fumarate/Emtricitabine; HIV, Human immunodeficiency virus; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0209911.g002
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fat/trunk fat (r = 0.31, P = 0.004/r = 0.28, P = 0.012) and baseline adiponectin with baseline
limb fat and total body fat (r = 0.4, P<0.001/r = 0.27, P = 0.01). Insulin resistance at baseline,
measured by the homeostatic model assessment (HOMA-IR), was also significantly correlated
with limb, trunk and total body fat mass (Table 2).
We then explored if changes in these markers between baseline and week 48 were related
with percentage changes in body composition variables at week 48. Again the strongest corre-
lations were between changes in insulin, leptin, and HOMA-IR with limb fat and total body fat
mass (Table 2).
We used multivariable mixed model to assess the rate of change in adipokines and
inflammatory markers between randomisation and week 48 in relation to percentage
change in body composition parameters (Table 3), after adjustment for treatment arm, his-
tory of fractures at baseline, nadir CD4, CD4 count and viral load at randomisation. In uni-
variable analyses, a faster increase in leptin was associated with an increase in limb fat,
trunk fat or total body fat mass at week 48, while a faster increase in HOMA-IR was associ-
ated with an increase in limb fat mass and total body fat mass. There was no evidence that
IL-6, adinopectin, FGF-23, IL1-beta and TNF-alpha were associated with changes in body
composition parameters in univariable analyses (p>0.1), and these were therefore not
included in multivariable models.
After adjustment, on average, a 10% faster increase in leptin between baseline and week 48
was associated with a more rapid increase in limb fat at week 48 (0.5% per 48 weeks, 95% CI
0.4, 0.6; p<0.001), a 0.6% per 48 weeks faster increase in total body fat mass (95% CI 0,5, 0.7;
p<0.001) and a 0.3% per 48 weeks faster increase in trunk fat mass (95% CI 0.1,0.4;
p = 0.0026). A faster increase in HOMA-IR was also associated with greater increases in limb
fat mass, trunk fat or total body fat mass (Table 3).
Discussion
In the present analysis we report a statistically significant greater increase in body mass index
and trunk fat in the DRV/r + RAL at week 96. We found that gains in limb and total body fat
peaked at 48 weeks in both arms and subsequently decreased except for trunk fat mass in the
DRV/r + RAL. These changes in body composition variables were related with leptin changes
during the first 48 weeks.
Table 2. Correlation between inflammatory markers and body composition parameters.
IL-6 (n = 87) Insulin (n = 84) Leptin (n = 87) Adiponectin
(n = 86)
FGF-23 (n = 85) HOMA-IR (n = 84)
Baseline R P R P R P R P R P R P
Limb fat -0.03 0.78 0.31 0.004 0.63 <0.001 0.40 <0.001 0.17 0.12 0.32 0.0035
Trunk fat -0.07 0.48 0.28 0.012 0.50 <0.001 0.08 0.44 0.09 0.39 0.25 0.023
Lean body mass 0.07 0.48 -0.13 0.25 -0.25 0.02 -0.14 0.20 -0.07 0.52 -0.09 0.41
Total body fat mass -0.06 0.59 0.32 0.0028 0.63 <0.001 0.27 0.01 0.15 0.17 0.31 0.0040
Percentage change at week 48 IL-6 (n = 69) Insulin (n = 64) Leptin (n = 64) Adiponectin
(n = 68)
FGF-23 (n = 64) HOMA-IR (n = 64)
Limb fat 0.16 0.2 0.46 <0.001 0.70 <0.001 -0.05 0.68 -0.00 0.99 0.31 0.014
Trunk fat 0.22 0.07 -0.23 0.072 0.27 0.03 -0.07 0.57 0.01 0.91 0.11 0.42
Lean body mass -0.16 0.18 -0.03 0.82 -0.08 0.51 0.03 0.83 -0.19 0.14 -0.04 0.76
Total body fat mass -0.15 0.23 0.46 <0.001 0.60 <0.001 -0.08 0.50 -0.04 0.75 0.33 0.0084
IL, interleukin; TNF, tumour necrosis factor; FGF, fibroblast growth factor 23; HOMA-IR, homeostatic model assessment-insulin resistance
https://doi.org/10.1371/journal.pone.0209911.t002
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There are limited data on the effect of integrase inhibitors containing regimens on body
composition in antiretroviral naïve patients. The STARTMRK study randomized HIV-
infected patients to efavirenz vs. raltegravir both with TDF/FTC. In a convenience sample of
86 participants at 48 weeks and 75 participants at 96 weeks, percentage changes in appendicu-
lar and trunk fat were similar between arms [6]. Those allocated to the TDF/FTC + RAL arm
had a 19% increase in trunk fat at week 48 and 21.6% at 96 weeks. In the ACTG 5260s study,
central and peripheral fat gains were similar in patients treated with raltegravir or the protease
inhibitors atazanavir or darunavir all in combination with TDF/FTC[7]. Those allocated to the
TDF/FTC + RAL arm had a 19.4% increase in trunk fat at week 96. Our study gave the oppor-
tunity to compare a NtRTI-containing and a NtRTI-sparing regimen, with a backbone of rito-
navir-boosted-darunavir.
We did not find significant differences in body changes from baseline between the RAL and
the TDF/FTC arm at week 96 except for trunk fat mass that was significantly higher in the N(t)
RTI sparing arm. In ACTG 5260s percentage change in limb fat and trunk fat at 96 weeks in
the DRV/r plus TDF/FTC arm were greater than in our study (14.2%, 20.8% vs. 4.9%, 9.8%).
These differences could be partially explained by patients’ baseline characteristics: slightly
older population (median age of 40 years vs. 36 years) and Caucasian origin in a majority of
participants (89% vs. 44%) in our study. In the STARTMRK baseline CD4 count was lower
than in our study (median of 212 cells/mm3 vs. 338 cells/mm3) and the return to health phe-
nomena could have played a more determinant role in the results. Differential effects on fat
redistribution across studies could also be explained by genetic determinants. This has been
suggested in the recent SECOND-LINE metabolic study where African participants were more
prone to lose fat in comparison with Asian participants[17].
Table 3. Associations between percentage change in biomarkers and percentage change in body composition from randomisation to 48 weeks.
Univariate Multivariate
Estimate 95% CI P-value Adjustedb
Estimate
95% CI P-value
Limb fat mass
Insulin 0.53 0.39, 0.67 <0.001 0.09 -0.05, 0–23 0.2
Leptin 0.61 0.53, 0.69 <0.001 0.52 0.42, 0.62 <0.001
HOMA-IR 0.34 0.19, 0.49 <0.001 0.17 0.05, 0.29 0.0065
RAL + DRV/r vs. TDF/FTC + DRV/r 8.86 -4.47, 22.19 0.2 2–30 -4.95, 9.55 0.54
Trunk fat mass
Insulin -0.32 -0.50, -0.14 0.0012 -0.48 -0.67, -0.29 <0–001
Leptin 0.32 0.17, 0.47 <0.001 0.25 0.10, 0.40 0.0026
HOMA-IR 0.10 -0.03, 0.23 0.14 0.25 0.12, 0.38 <0.001
RAL + DRV/r vs. TDF/FTC + DRV/r -1.60 -9.54, 6.34 0.69 -4.90 -12.90, 3.10 0.23
Total body fat mass
Insulin 0.50 0.35, 0.65 <0.001 0.03 -0.12, 0.18 0.7
Leptin 0.64 0.55, 0.73 <0.001 0.59 0.49, 0.69 <0.001
HOMA-IR 0.32 0.17, 0.47 <0.001 0.17 0.04, 0.30 0.011
RAL + DRV/r vs. TDF/FTC + DRV/r 9.05 -0.75, 18.85 0.072 1.23 -6.49, 8.95 0.76
The estimates show the association between biomarkers and measures of body composition from mixed models which estimate the rate of percentage change in body
composition (limb fat mass, trunk fat mass or total body fat mass) per 48 week period associated with a 10% change in the change in biomarkers over the same time
period.
bAdjusted additionally for fractures at baseline, nadir CD4+, CD4+ count and viral load at randomisation. DRV/r +RAL: darunavir/ritonavir plus raltegravir. DRV/r
+ TDF/FTC: darunavir/ritonavir plus tenofovir/Emtricitabin. HOMA-IR, homeostatic model assessment-insulin resistance
https://doi.org/10.1371/journal.pone.0209911.t003
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In the NEAT 001/ANRS 143 study participants randomized to the RAL group tended to
have higher increases in limb, trunk and total body fat mass as well as higher increases in BMI
over 96 weeks than participants randomized to the TDF/FTC group. Two other studies have
reported body composition changes associated to initial treatment with a N(t)RTI sparing regi-
men consisting of an integrase strand-transfer inhibitor plus a ritonavir-boosted protease
inhibitor. In the PROGRESS study increases in peripheral and trunk fat were greater in
patients treated with lopinavir/ritonavir plus raltegravir arm compared to patients treated with
lopinavir/ritonavir plus tenofovir disoproxil fumarate/emtricitabine, although this difference
was only significant for peripheral fat, both in arms and legs [9]. In the RADAR study[10],
with a smaller sample size and only data at 48 weeks, there was a non significant greater
increase in total body fat in the DRV/r + RAL arm compared to DRV/r + TDF/FTC. Data on
trunk fat were not provided. These two studies had a virologic primary endpoint and therefore
may have been underpowered to detect differences in body composition variables. All these
studies focusing on the effect of raltegravir-based regimens in naïve HIV-infected patients on
body composition variables show a differential effect when RAL is used with or without TDF/
FTC. The present substudy was specifically designed to find differences in bone mineral den-
sity and body composition variables between treatment arms. Combined results of NEAT 001/
ANRS143, PROGRESS and RADAR suggest that the greater increase in body composition fat
variables observed in patients receiving N(t)RTI sparing regimens could be related to the
avoidance of a deleterious effect on fat of TDF/FTC. It has been reported that TDF/FTC
decreases both mitochondrial DNA in fat biopsies and the activity of mitochondrial oxidative
phosphorylation enzymes[4].
Data about the relationship between insulin, adipokines, and body composition changes in
HIV-infected patients are limited. In the ACTG 5260 higher levels of inflammatory markers at
baseline were associated with increases in peripheral fat and lean body mass but not central
adiposity[7]. In this trial, lower baseline leptin level, higher adiponectin and higher viral load
were associated with greater gains in visceral adipose tissue, although the association with adi-
ponectin was marginal. In our study we found, as expected, a positive correlation between
baseline insulin and leptin levels and limb, trunk and total body fat. After adjustment, a 10%
increase in leptin from baseline was correlated with a highly significant increase in limb fat
mass at week 48 independently of treatment arm. Associations between circulating adipokines
and visceral fat are not always robust[18]. The discrepancies between NEAT 001/ANRS 143
and ACTG 5260 may be due to participants’ characteristics. In NEAT 001/ANRS 143 partici-
pants were mostly Caucasians and had lower BMI, lower limb fat, trunk fat and lean body
mass at baseline. In ACTG 5260 percentage of moderate physical exercise was roughly 80% in
the three arms. We cannot exclude a differential contribution of physical exercise among these
studies although in our study physical exercise was not associated with percentage change n
body composition variables.
Other studies have reported an association between inflammation and visceral/subcutane-
ous adipose tissue [19,20]. Recent findings suggest that chronic inflammation could partially
influence long-term body composition changes. In a study of malnourished African patients, a
one log reduction in CRP was associated with almost 600 grams increase in fat-free mass after
6 weeks of starting ART[21]. We did not find associations between IL-6 and body composition
changes in our study and this could be explained by the smaller sample size, the good health at
baseline and the recent HIV diagnosis (median HIV duration 1.8 years) of NEAT 001/ANRS
143 participants.
Our study has several limitations. Participants were mainly Caucasian males and therefore
the results might not be generalizable. DXA measures were locally but not centrally calibrated
and there was no central reading. We did not have accurate data on visceral adiposity because
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we did not perform CT scans, however in the recent ACTG 5260s trial there was a good corre-
lation between visceral adiposity measured by CT scan and trunk fat measured by DXA so we
consider this limitation should not greatly influence our results. Sample size was calculated for
bone mineral density changes and therefore we could have had insufficient power to detect
mild differences in the body composition variables between arms. Another limitation is that
inflammatory markers and adipokines were only measured in a limited subset of participants.
In summary, after 96 weeks a N(t)RTI sparing regimen of DRV/r + RAL produced a
numerically greater percentage increase in body composition variables, with change in trunk
fat mass and BMI being significant, compared to the TDF/FTC + DRV/r regimen. Changes in
leptin levels during the first 48 weeks were correlated with changes in limb, trunk and total
body fat independently of treatment arm. Future adequately powered studies with longer fol-
low-up are needed to better understand the interplay between modern antiretroviral drugs
and visceral adiposity.
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